Emerging therapeutic targets for viral gene expression inhibition.

Zhang Nasa*

Department of Biomedical Engineering, IIT Hyderabad, Kandi, Sangareddy, Telangana 502285, India

Introduction

Viral infections are a significant public health problem worldwide. Many viruses have developed strategies to evade the host immune response and persist within the host organism. One strategy that viruses use is to manipulate the host cell's gene expression machinery to their advantage. As such, targeting viral gene expression is an attractive therapeutic approach for the treatment of viral infections. Here, we will discuss emerging therapeutic targets for viral gene expression inhibition.

HDACs are enzymes that regulate gene expression by removing acetyl groups from histone proteins. This process can repress or activate transcription of genes. Many viruses have been shown to utilize HDACs for gene expression regulation. For instance, the human immunodeficiency virus (HIV) encodes a protein, Tat, which recruits HDACs to the viral promoter, leading to transcriptional repression of host immune genes. Inhibitors of HDACs have shown promise as antiviral agents in vitro, and clinical trials are ongoing. RNAi is a cellular mechanism of gene regulation that uses small interfering RNAs (siRNAs) to target and degrade specific messenger RNAs (mRNAs). Viruses, including human cytomegalovirus (HCMV), have developed strategies to evade the host RNAi machinery, allowing for viral gene expression. However, RNAi has been exploited as a therapeutic approach to target viral gene expression [1]. Small RNA molecules can be designed to target specific viral mRNAs, leading to their degradation and inhibition of viral replication. RNAi-based therapies are in clinical trials for several viral infections, including hepatitis B and C viruses. RNA viruses encode RdRps, which are essential for viral replication. These enzymes catalyze the synthesis of viral RNA from a template of viral RNA. RdRps are excellent targets for antiviral therapy as they are specific to viral replication and essential for the viral life cycle. Small molecule inhibitors of RdRps have been developed for several viruses, including hepatitis C and influenza viruses.

Many viruses require proteases for viral replication. For example, the hepatitis C virus encodes a protease that cleaves viral polyproteins into functional viral proteins. Protease inhibitors can block this cleavage, thereby inhibiting viral replication. Protease inhibitors have been developed for several viruses, including HIV and hepatitis C virus. Helicases are enzymes that unwind double-stranded nucleic acids during replication and transcription. Viral helicases are essential for viral replication, making them a target for antiviral therapy. Several helicase inhibitors have been developed for different viruses, including hepatitis C virus. Transcription factors are proteins that bind to DNA and regulate gene expression. Many viruses, including herpes simplex virus type 1 (HSV-1), encode transcription factors that modulate host gene expression. Inhibiting viral transcription factors has been shown to be an effective antiviral strategy. Small molecule inhibitors of HSV-1 transcription factors are currently in clinical trials [2].

Integrase is an enzyme that integrates viral DNA into the host genome during viral replication. It is an essential enzyme for the life cycle of retroviruses, including HIV. Integrase inhibitors have been developed for HIV therapy and have been shown to be highly effective in clinical trials. Many viruses require fusion of the viral envelope with the host cell membrane to enter the cell. Viral fusion proteins are critical for this process and are attractive targets for antiviral therapy. Small molecule inhibitors of viral fusion proteins have been developed for several viruses [3].

In conclusion, emerging therapeutic targets for viral gene expression inhibition have the potential to revolutionize the treatment of viral infections. By targeting various steps in the viral gene expression pathway, including transcription, translation, and post-transcriptional modifications, these new therapies offer a range of options for disrupting the replication and spread of viruses. Additionally, some of these therapies may have the added benefit of reducing the likelihood of viral resistance, as they target conserved steps in the viral gene expression pathway. Continued research into the mechanisms of viral gene expression and the development of new therapies will be essential for combating the ongoing threat of viral infections [4,5].

References

1. Cao X, Coyle JP. Invited review: human air-liquid-interface organotypic airway tissue models derived from primary tracheobronchial epithelial cells-overview and perspectives. In Vitro Cell Dev Biol Anim. 2021;57:104-132.
2. Tan Q. Human airway organoid engineering as a step toward lung regeneration and disease modelling. Biomaterials. 2017;113:118-32.
3. Ruge CA, Cañadas O. The interplay of lung surfactant proteins and lipids assimilates the macrophage clearance of nanoparticles. PLoS One.2012;7:e40775.

***Correspondence to:** Zhang Nasa, Department of Biomedical Engineering, IIT Hyderabad, Kandi, Sangareddy, Telangana 502285, India, E-mail: zhang@bme.iith.ac.in

***Received**: 25-Apr-2023, Manuscript No. AAVRJ-23-97696; **Editor assigned**: 26-Apr-2023, PreQC No. AAVRJ-23-97696(PQ); **Reviewed**: 10-May-2023, QC No. AAVRJ-23-97696; **Revised**: 17-May-2023, Manuscript No. AAVRJ-23-97696(R); **Published**: 24-May-2023, DOI:10.35841/AAVRJ-7.3.142*

***Citation:** Nasa Z. Emerging therapeutic targets for viral gene expression inhibition. Virol Res J. 2023;7(3):142*

4. Al-Ahmady ZS, Al-Jamal WT. Lipid-peptide vesicle nanoscale hybrids for triggered drug release by mild hyperthermia in vitro and in vivo. ACS Nano.2012;6:9335-46.
5. Zhu E. Surface-functionalized PEGylated nanoparticles deliver messenger RNA to pulmonary immune cells. ACS Appl Mater Interfaces. 202012:35835-44.

Citation: *Nasa Z. Emerging therapeutic targets for viral gene expression inhibition. Virol Res J. 2023;7(3):142*